Midazolam
- Generic Name
- Midazolam
- Brand Names
- Buccolam, Busulfex, Nayzilam, Seizalam
- Drug Type
- Small Molecule
- Chemical Formula
- C18H13ClFN3
- CAS Number
- 59467-70-8
- Unique Ingredient Identifier
- R60L0SM5BC
- Background
Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called benzodiazepines. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by oral, rectal, intranasal...
- Indication
Midazolam has different indications depending on its formulation by the FDA.
Nasal
...
- Associated Conditions
- Epileptic seizure, Status Epilepticus
- Associated Therapies
- Anaesthesia, Anxiolytic therapy therapy, Sedation for mechanically-ventilated patients, Preoperative amnesia therapy, Preoperative sedation therapy
A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Drug-drug Interaction of VX-993 in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 42
- Registration Number
- NCT06392659
- Locations
- 🇬🇧
MAC Clinical Research, Manchester, United Kingdom
A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood
- Conditions
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT06367153
- Locations
- 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium
A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Bayer
- Target Recruit Count
- 15
- Registration Number
- NCT06360211
- Locations
- 🇺🇸
Parexel Baltimore - Early Phase Clinical Unit, Baltimore, Maryland, United States
Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Jemincare
- Target Recruit Count
- 72
- Registration Number
- NCT06348290
A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of VX-407 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 95
- Registration Number
- NCT06345755
- Locations
- 🇺🇸
ICON Lenexa, Lenexa, Kansas, United States
A Study in Healthy People to Test How Well Different Doses of BI 3000202 Are Tolerated and How They Affect the Way the Body Handles Midazolam
- First Posted Date
- 2024-03-25
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 40
- Registration Number
- NCT06327256
- Locations
- 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium
Intrathecal Dexmedetomidine vs Midazolame
- Conditions
- Interventions
- First Posted Date
- 2024-03-18
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- National Cancer Institute, Egypt
- Target Recruit Count
- 75
- Registration Number
- NCT06315634
- Locations
- 🇪🇬
National cancer institute, Cairo, Egypt
ECC5004 DDI Study With Atorvastatin, Rosuvastatin, Digoxin and Midazolam in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Eccogene
- Target Recruit Count
- 48
- Registration Number
- NCT06293742
- Locations
- 🇺🇸
Eccogene Investigational Site, Anaheim, California, United States
A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Takeda
- Target Recruit Count
- 20
- Registration Number
- NCT06290050
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 122
- Registration Number
- NCT06279234
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸Qps-Mra, Llc, South Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.